MedTrace Logo

Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male Participants

NCT03004768 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2018-02-12

No results posted yet for this study

Summary

An oral dose in healthy subjects to obtain information about the absorption, metabolism, and excretion (AME) of BMS-986165

Conditions

Interventions

DRUG

BMS-986165

Oral solution dose of 24 mg \[14C\] BMS-986165 containing approximately 100 micro Ci of TRA

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-26
Primary Completion
2017-02-27
Completion
2017-02-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03004768 on ClinicalTrials.gov